Login
$LSTA
$1.10 +$0.01 (0.92%) After hours

$LSTA SEC Filings

Filed On Filing
13 Nov 2026 10-Q
12 Nov 2026 S-3
12 Nov 2026 S-8
12 Nov 2026 8-K/A: Financial Statements and Exhibits

We have audited the combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. (together, “the Company”), which comprise the combined balance sheets as of December 31, 2025 and 2024, and the related combined stat...

09 Nov 2026 DEFA14A
09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

The name of the plan is the Lisata Therapeutics, Inc. 2026 Equity Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultan...

19 Oct 2026 ARS
19 Oct 2026 Proxy statement: annual meeting on November 9, 2026

CEO pay $1.1M, down 32% · say-on-pay vote

15 Oct 2026 Form 3: Farrow Jeffrey S, Director

Holds 0 shares of No securities are beneficially owned

14 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee

07 Oct 2026 PRE 14A
02 Oct 2026 D
28 Sep 2026 Form 3: Love Ted W, Director

Holds 19,260 shares of Common Stock

28 Sep 2026 Form 3: Lehrer-Graiwer Joshua, President & COO

Holds 21,548 shares of Common Stock

17 Sep 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more

THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of September 17, 2026, by and among Lisata Therapeutics, Inc., a Delaware corporation (“Parent”), Mariner Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiar...

26 Aug 2026 SCHEDULE 13G
06 Aug 2026 10-Q
04 Aug 2026 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

We are pleased to inform you that, in recognition of your contributions to Lisata Therapeutics, Inc. (the “Company”), you are being offered the opportunity to receive a retention bonus (the “Retention Bonus”) on the following terms and c...

28 Jul 2026 SC TO-T/A
24 Jul 2026 8-K: Termination of a Material Definitive Agreement; Other Events

On July 24, 2026, Lisata Therapeutics, Inc. (the “Company”) terminated the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Kuva Labs Inc., a Delaware corporation (“Parent”) and Kuva Acquisition ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support